A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC)

Inclusion Criteria:

- Histologically-confirmed MBC not deemed amenable to curative surgery or curative
radiation therapy

- Tumors are positive for ER, PgR, or both

- Tumors must be negative for HER2 (by FISH, CISH or IHC)

- Female gender and age ≥ 18 years at time of study entry

- Postmenopausal

- Karnofsky Performance Status ≥ 70

- Life expectancy of ≥ 6 months

Exclusion Criteria:

- Subjects who received prior chemotherapy, hormonal therapy, immunotherapy or biologic
therapy for advanced or metastatic disease with the following exceptions:

- Prior adjuvant therapy with an AI and/or tamoxifen is allowed, provided
treatment ended at least 2 weeks prior to the first dose of MEDI-573

- Prior neoadjuvant and/or adjuvant chemotherapy for breast cancer is allowed

- Extensive symptomatic visceral disease including hepatic involvement and pulmonary
lymphangitic spread of tumor, or disease that is considered by the investigator to be
rapidly progressing or life threatening (eg, subjects who are intended for
chemotherapy)

- Active brain metastases with the exception of subject has been treated and are
asymptomatic and there has been no evidence of CNS progression for at least 4 weeks
of first dose of MEDI-573

- Evidence of ongoing spinal cord compression or leptomeningeal carcinomatosis

- Unresolved toxicities from prior therapy with the exception of alopecia that have not
resolved to ≤ Grade 1 at the time of starting study treatment

- Previous treatment with agents that target the IGF receptor

- History of allergy or reaction attributed to compounds of chemical or biologic
composition similar to those of MEDI-573 or AI

- History of another invasive malignancy within 5 years except for curatively resected
nonmelanoma skin cancer or carcinoma in situ of the cervix

- Poorly controlled diabetes mellitus